Statement re Change of Corporate Adviser
05 Septiembre 2024 - 1:00AM
UK Regulatory
Statement re Change of Corporate Adviser
DXS INTERNATIONAL PLC
(AQSE: DXSP)
Change of Adviser
DXS International plc (AQSE: DXSP) ("DXS" or the
"Company"), the digital clinical decision support company, is
pleased to announce that it has appointed Hybridan LLP as its AQSE
Corporate Adviser with immediate effect. Hybridan remains AQSE
Corporate Broker to the Company.
The Directors of DXS accept responsibility for
the contents of this announcement.
This announcement contains information which,
prior to its disclosure, was inside information as stipulated under
Regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations
2019/310 (as amended).The Directors of DXS International plc accept
responsibility for this announcement
Contacts:
David Immelman
Chief Executive
DXS International
plc
david@dxs-systems.com
https://www.dxs-systems.co.uk
Tel: 01252 719800
Claire Louise Noyce
AQSE Stock Exchange Corporate Adviser & Corporate
Broker
Hybridan
LLP
claire.noyce@hybridan.com
www.hybridan.com
Tel: +44 20 3764 2341
About DXS:
DXS International presents up to date treatment
guidelines and recommendations, from Clinical Commissioning Groups
and other trusted NHS sources, to doctors, nurses and pharmacists
in their workflow and during the patient consultation. This
effective clinical decision support ultimately translates to
improved healthcare outcomes delivered more cost effectively and
which should significantly contribute towards the NHS achieving its
projected efficiency savings.
DXS (AQSE:DXSP)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024
DXS (AQSE:DXSP)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024